Twist Bioscience is a technology company.
Twist Bioscience has raised $166.0M across 5 funding rounds.
Key people at Twist Bioscience.
Twist Bioscience has raised $166.0M in total across 5 funding rounds.
Twist Bioscience has raised $166.0M in total across 5 funding rounds.
Twist Bioscience's investors include Byers Capital, Fifth Wall, Merus Capital, Practical Venture Capital, Streamlined Ventures, Susa Ventures, TSVC Capital, Adam Jackson, Don Hutchison, Biomatics Capital Partners, ENIAC Ventures, Flagship Ventures.
Key people at Twist Bioscience.
# Twist Bioscience: High-Level Overview
Twist Bioscience is a biotechnology company that manufactures synthetic DNA using a proprietary silicon-based platform.[1] The company develops and sells a broad range of synthetic DNA-based products and services, including synthetic genes, next-generation sequencing (NGS) tools, antibody libraries for drug discovery, and reagents for genomics research.[1][2] Twist serves researchers and organizations across healthcare, industrial chemicals, agriculture, and academic research by enabling the engineering of biology at scale.[1]
The company solves a fundamental problem in synthetic biology: the need for rapid, high-quality, and scalable DNA synthesis. Traditional DNA manufacturing methods are slow and expensive; Twist's silicon-based approach dramatically accelerates production by "writing" DNA directly onto semiconductor chips, enabling the synthesis of thousands of genes daily.[1] This technological advantage positions Twist as a critical infrastructure provider in the growing synthetic biology ecosystem, supporting everything from basic research to clinical drug development.
# Core Differentiators
# Role in the Broader Tech Landscape
Twist operates at the intersection of two powerful trends: the exponential growth in genomics research and the industrialization of synthetic biology. As DNA sequencing costs have plummeted, demand for synthetic DNA has surged—researchers need tools to design, test, and manufacture genetic constructs at scale. Twist's silicon-based platform addresses this bottleneck by making DNA synthesis faster and more affordable, effectively democratizing access to synthetic biology capabilities.
The company's infrastructure role is particularly significant: by enabling researchers to rapidly prototype genetic designs, Twist accelerates innovation across pharmaceutical development, agricultural biotechnology, and industrial bioengineering. This positions the company as a foundational technology provider whose impact extends far beyond its direct customers, influencing the pace of discovery across the life sciences.
# Quick Take & Future Outlook
Twist Bioscience is well-positioned to benefit from the continued expansion of synthetic biology and genomics-driven drug discovery. As pharmaceutical companies increasingly rely on engineered biologics and personalized medicine, demand for high-quality, scalable DNA synthesis will likely grow. The company's longer-term ambitions—including digital data storage in DNA and biologics drug discovery—suggest management is thinking beyond current markets toward emerging applications that could unlock entirely new revenue categories.
The key question for Twist's trajectory is whether its silicon-based manufacturing advantage can be sustained as competitors enter the space, and whether the company can successfully expand from being a tools provider into higher-margin areas like drug discovery itself. Success in these areas would transform Twist from an important infrastructure company into a more diversified biotechnology player with direct exposure to drug development upside.
Twist Bioscience has raised $166.0M across 5 funding rounds. Most recently, it raised $33.0M Venture Round in March 2017.
